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We developed the transcription factor (TF)-target
gene database and the Systems Genetics Network
Analysis (SYGNAL) pipeline to decipher transcrip-
tional regulatory networks from multi-omic and clin-
ical patient data, and we applied these tools to 422
patients with glioblastoma multiforme (GBM). The
resulting gbmSYGNALnetworkpredicted 112 somat-
ically mutated genes or pathways that act through 74
TFs and 37 microRNAs (miRNAs) (67 not previously
associated with GBM) to dysregulate 237 distinct
co-regulated gene modules associated with patient
survival or oncogenic processes. The regulatory
predictions were associated to cancer phenotypes
using CRISPR-Cas9 and small RNA perturbation
studies and also demonstrated GBM specificity.
Two pairwise combinations (ETV6-NFKB1 and romi-
depsin-miR-486-3p) predicted by the gbmSYGNAL
network had synergistic anti-proliferative effects.
Finally, the network revealed that mutations in NF1
and PIK3CA modulate IRF1-mediated regulation of
MHC class I antigen processing and presentation
genes to increase tumor lymphocyte infiltration and
worsen prognosis. Importantly, SYGNAL is widely
applicable for integrating genomic and transcrip-
tomic measurements from other human cohorts.
INTRODUCTION
Glioblastomamultiforme (GBM) is themost common brain tumor
and is nearly uniformly fatal. Development of new therapeutics
has been slow and difficult (Alexander et al., 2013), in part
because GBM is a complex and heterogeneous disease
(Brennan et al., 2013). One possible strategy to achieve com-
plete and durable remission is to tailor a combination of drugs
that targets multiple vulnerabilities in a patient’s tumor. What is
needed to test this strategy is an approach that navigates the
large space of possible drug combinations and prioritizes spe-
cific drug combinations based on the molecular signatures of a172 Cell Systems 3, 172–186, August 24, 2016 ª 2016 The Authors.
This is an open access article under the CC BY license (http://creativepatient’s tumor. We hypothesized that knowledge of the detailed
architecture of transcription factor (TF) and microRNA (miRNA)
regulatory interactions in the form of a transcriptional regulatory
network (TRN) would provide the mechanistic details required to
prioritize combinatorial interventions. Both TFs (Cai et al., 1996)
and, more recently, miRNAs (Bouchie, 2013) have been used as
therapeutic targets. In fact, consistent with the situation 20
years ago (Cai et al., 1996), therapies targeting TFs still comprise
14% of the top 50 best-selling FDA-approved drugs in 2014.
Additionally, therapies targeting TFs and miRNAs have the po-
tential for a broader effect than those targeting a single gene,
as these regulators control many genes associated with diverse
oncogenic biological processes.
Previous efforts on the inference of TRNs for cancers have
relied on the discovery of correlates or mutual information be-
tween different features within multi-omics datasets from patient
tumors (Carro et al., 2010; Sumazin et al., 2011). Additionally, the
integration of genetic markers with expression data has been
used to infer causal relationships that explain the flow of informa-
tion from a somatic mutation or copy number variation to its
downstream effect on gene expression traits (Chen et al.,
2014; Jo¨rnsten et al., 2011). We and others have used mecha-
nism-based strategies to link TFs and miRNAs to co-regulated
sets of genes through enrichment of physical binding site
sequences in the regulatory regions of co-expressed genes in
cancers (Goodarzi et al., 2009; Plaisier et al., 2012; Reiss et al.,
2015). Many of these approaches are complementary and
have yet to be integrated into a unified TRN inference pipeline
(Table S1).
Until now the synthesis of mechanistic and causal inference
approaches has been difficult, owing to the lack of high-quality
mechanistic regulatory inference approaches and large-scale
multi-omic datasets. Here we addressed the first issue of infer-
ring high-quality mechanistic regulatory interactions by using
recently published compendia of TF binding motifs and Encyclo-
pedia of DNA Elements (ENCODE) data to develop a TF-target
gene database, which is a key input for TRN inference methods
we developed previously (Plaisier et al., 2012; Reiss et al., 2015).
The second issue has been addressed by agencies like The
Cancer Genome Atlas (TCGA), having created large-scale
multi-omic datasets for a wide array of cancers. Thus, the avail-
ability of the prerequisite tools and datasets enabled us to
develop the Systems Genetics Network Analysis (SYGNAL)Published by Elsevier Inc.
commons.org/licenses/by/4.0/).
pipeline. The pipeline integrates correlative, causal, and mecha-
nistic inference approaches to infer the causal flow of informa-
tion frommutations to regulators (TFs and miRNAs) to perturbed
gene expression patterns across patient tumors (Table S1).
Importantly, because the algorithms behind each component
of the SYGNAL pipeline have been rigorously tested and vali-
dated in prior studies (Aten et al., 2008; Brooks et al., 2014;
Friedman et al., 2009; Kertesz et al., 2007; Reiss et al., 2015),
we were able to focus on validating the TF andmiRNA regulatory
predictions, demonstrating how these predictions from patient
data can be used to prioritize single and combinatorial interven-
tions and showing how the GBM TRN can be used to glean
biological insights with a vignette focusing on the regulation of
tumor lymphocyte infiltration in GBM.
RESULTS
Inference of a Comprehensive Mechanistic Human TF-
Target Gene Interaction Database
To enable the inference of mechanistic TF-mediated regulation
of co-expressed transcripts, we constructed a database of TF-
to-target gene interactions. The TF-to-target gene interactions
were discovered by intersecting the locations of 2,331 unique
DNA recognition motifs for 690 TFs across the human genome
(Matys et al., 2006; Newburger and Bulyk, 2009; Jolma et al.,
2013; Mathelier et al., 2014) and ENCODE-determined 8.4
million genomic sites with digital genomic footprints (DGFs)
across 41 diverse cell and tissue types (Neph et al., 2012).
A DGF is experimental evidence that a DNA-binding protein
was bound to a genomic location, and, when coincident with a
motif instance, it suggests an interaction of a specific TF with
that genomic location (Figure 1A). We discovered 17,415,125
genomic locations within the optimal promoter region of human
genes (±5 kb from the transcriptional start site [TSS], see below)
that matched significantly to a TF DNA recognition motif (finding
individual motif occurrences [FIMO] p value % 1 3 105; Fig-
ure 1A). The 3,505,491 motif instances that overlapped by at
least 1 bp with a DGF were used to construct a map of inter-
actions between the 690 TFs and 18,153 genes (Figure 1A; TF-
target gene interactions and motif-to-TF mappings are available
at http://tfbsdb.systemsbiology.net).
We then systematically evaluated the sensitivity and speci-
ficity of the inferred regulatory interactions by comparing the
predicted TF-target gene interactions against a gold standard
physical map of protein-DNA interactions for 125 different
TFs, constructed from 148 chromatin immunoprecipitation
sequencing (ChIP-seq) experiments across 68 cell lines (Fig-
ure 1B; Wang et al., 2012). Specifically, we tested the ability of
the inferred regulatory interactions to predict the TF that was tar-
geted for ChIP from ChIP-seq-enriched genomic locations in
each experiment. We chose this comparison as it mirrors how
the interactions are used to infer TF-mediated regulation of
co-expressed genes.
First, we established that the optimal promoter region
for predicting TF-DNA interactions using this approach was
±5 kb from the TSS, by systematically analyzing specificity
and sensitivity of predictions across increasing promoter
lengths compared to a core promoter (i.e., ±500 bp of the
TSS; Xie et al., 2005; Figures S1A and S1B; details are givenin the Supplemental Experimental Procedures). Next, we
demonstrated that the sensitivity and specificity of predicting
TF-target gene interactions improves significantly when motif
instances are filtered based on DGF locations (unfiltered
receiver operating characteristic area under the curve [ROC
AUC] = 0.74; filtered ROC AUC = 0.85; comparison p value =
6.9 3 108; Figure S1C). Notably, TF-target gene interactions
accurately predicted the immunoprecipitated TF even in the
48 cell lines and tissues that were not represented within the
ENCODE compendium of DGF profiles (DGF-profiled ROC
AUC = 0.85, not profiled ROC AUC = 0.82, comparison
p value = 0.24). This result demonstrated that the collection
of DGF profiles from 41 cell types within ENCODE had
captured transcriptional regulation by most TFs across most
cell types, including those that were not DGF profiled.
Importantly, the specific cell type and context for a given set
of TF-target gene interactions can be recovered post hoc by
analyzing the patterns of conditional co-expression of the target
genes. We accomplished this using the set-enrichment scoring
module in the cMonkey2 biclustering algorithm, which discovers
the most enriched TF and trains each bicluster by preferentially
retaining and adding co-expressed genes with the enriched
TF’s binding sites (Figures 1C and 2A). This approach with
cMonkey2 also can be used to discover miRNA-mediated
regulation using an miRNA-target gene database (PITA or
TargetScan) as input for the set-enrichment scoring module
(Figure 2A).
Constructing a TRN for GBM
We have used patient data for GBM to develop the SYGNAL
pipeline by integrating themethodology for constructing amech-
anistic TF-target gene interaction database (described above)
with previously developed multi-omics data mining methodolo-
gies (Figure 2A). The SYGNAL pipeline constructs a TRN in
four steps that are described briefly here and in detail in the
Supplemental Experimental Procedures. First, simultaneous
dimensionality reduction and inference of mechanistic TF- and
miRNA-mediated regulation of biclusters (co-regulated gene
modules) are based on the enrichment of a regulator’s binding
sites using the cMonkey2 biclustering algorithm (Plaisier et al.,
2012; Reiss et al., 2015). Second, post-processing of biclusters
provides additional information about regulators, enrichment
with functional categories, association with hallmarks of cancer,
and association with patient survival. Filtering on the post-pro-
cessed features ensures co-expression quality and disease rele-
vance. Third, causal regulatory interactions are inferred, linking
somatically mutated genes or pathways with the modulation of
a TF or miRNA to the regulation of a downstream bicluster based
on the fitting of casual graphical models that integrate genomic
and transcriptomic data (network edge orienting [NEO]; Aten
et al., 2008; Plaisier et al., 2009). In the fourth and final step,
we integrate the mechanistic and causal predictions for TF-
and miRNA-mediated regulation of biclusters.
We applied the SYGNAL pipeline to multi-omics data from
TCGA for GBM across 422 patients and nine normal post-mor-
tem controls to infer an integrated TF and miRNA regulatory
network (Figure S2A) (Brennan et al., 2013). The TCGA multi-
omics data were refined at each omic level to enhance the
signal-to-noise ratio (described in detail in the SupplementalCell Systems 3, 172–186, August 24, 2016 173
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Figure 1. Construction of Genome-wide TF-Target Gene Interaction Database by Integrating Genomic Sequence, TF DNA Recognition
Motifs, and DGFs
(A) Promoter regions of genes (±5 kb of the transcriptional start site [TSS]) were searched for DNA sequences that significantly matched a TF DNA recognition
motif. DNase I hypersensitivity hotspots were used to provide information about which regions of a promoter have open chromatin. DGFs were used to provide a
means to empirically determine the genome-wide occupancy of DNA by TFs and other factors at nucleotide resolution. The requirement that a DGF overlaps with
a motif instance can be used to exclude a large fraction of motif instances that are unlikely to be bound by a TF.
(B) We compared our predicted TF-target gene interactions to empirically determined TF binding from ChIP-seq studies.
(C) TF- or miRNA-target gene predictions were compiled into a database (TF-target gene database described in A and miRNA-target gene databases are PITA
and TargetScan). Mechanistically based TF- andmiRNA-mediated regulation was inferred by integrating the target gene databases into the newly developed set-
enrichment scoring module for cMonkey2, which systematically retains and adds co-expressed target genes of an enriched regulator.Experimental Procedures). We discovered 500 biclusters (of
1,830 biclusters) of genes that were significantly co-expressed
across different subsets of patient tumors (in the TCGA and at
least one independent GBM cohort) and were disease relevant
(significantly associated with patient survival or a hallmark
of cancer; Figure 2B; Figure S2A; Tables S2, S3, and S4). The174 Cell Systems 3, 172–186, August 24, 2016SYGNAL pipeline also inferred causal influences for somatically
mutated genes and pathways on the expression of TFs and
miRNAs, which in turn were predicted to modulate the expres-
sion of co-regulated genes within one of the 500 biclusters
(i.e., somatic mutation/ TF or miRNA/ bicluster; Figure 2B;
Figures S2B and S2C).
AC
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Using this approach, somatic mutations within 34 genes
and 68 pathways were causally associated, through TFs and
miRNAs, to the differential regulation of disease-relevant genes
(Figure 2B; Figure S2; Table S5). Notably, nine of the 34 mutated
genes are well-known driver mutations in GBM (Gonzalez-Perez
et al., 2013): AHNAK2, EGFR, IDH1, MLL3, NF1, PIK3CA,
PIK3R1, PTEN, and RB1 (Figure 2C). The SYGNAL pipeline-
derived network identified additional GBM driver mutations in
25 genes and 68 pathways that putatively act via modulating
the activity of TFs andmiRNAs, which in turn regulate the expres-
sion of 5,193 disease-relevant genes associated with patient
survival and/or hallmarks of cancer. Thus, the SYGNAL pipeline
provides the means to synthesize genotype, gene expression,
and clinical information into a TRN (the gbmSYGNAL network)
with both mechanistic and causal underpinnings to explain
how specific mutations act through TFs andmiRNAs to generate
disease-relevant gene expression signatures observed within
patient data (Figure 2C). As part of the post-processing,
we extended predicted influences of a TF to its paralogs by
assuming that the motifs within a TF family would not vary signif-
icantly (Wingender et al., 2013). Inclusion of TFs via expanded
family memberships resulted in an 1.5-fold increase in the
number of TFs (51 to 74) that were incorporated into the network
with both mechanism-based and causality-based evidence for
regulation (p value = 5.0 3 105; Figure 2C; Table S6). Thus,
the gbmSYGNAL network predicted at least one TF or miRNA
as a regulator responsible for co-regulating genes within 237 of
the 500 disease-relevant biclusters.
TF Regulation in the gbmSYGNAL Network
To test gbmSYGNAL predictions, we extracted phenotype data
for 1,445 TF knockouts (96% of known TFs) from our recent
genome-wide CRISPR-Cas9 screen, where we assayed conse-
quences of each perturbation on the proliferation phenotype of
two patient-derived glioma stem cell isolates (0131 and 0827)
and two control neural stem cell lines (CB660 and U5) (Toledo
et al., 2015; Figure 2C; Table S7). In total, knockout of 387 TFs
significantly altered proliferation in glioma stem cell isolates
(false discovery rate [FDR]% 0.05), of which the effects of knock-
ing out 158 TFs were glioma specific (i.e., significant effects in
glioma stem cell isolates, but not in neural stem cells). The
gbmSYGNAL network was significantly enriched with 26 TFsFigure 2. The SYGNAL Pipeline and the Construction of the gbmSYGN
(A) Regulatory influences from target gene databases (this study) and patient tum
three steps by a suite of interconnected algorithms in the Systems Genetics Net
(B) The gbmSYGNAL transcriptional regulatory network (TRN) was constructed b
with different subtypes of GBM. The resulting TRN is a predictive map that implica
ormiRNA(s) that in turn regulates genes (within a bicluster) that are putatively asso
gbmSYGNAL TRN is shown on the left.
(C) A gbmSYGNAL sub-network of 242 biclusters, each of which has at least one
hierarchical layout described in (B) and uses the same symbols and colors for netw
(e.g., somatically mutated gene or pathway), phenotypic demonstration (CRISP
highlight a single path through the network that is discussed in detail (bold ed
expression of IRF1, which in turn is predicted to regulate PITA_282 bicluster ge
processes (tumor immunity and growth signaling). In addition, we highlight miRN
tablished inhibitor therapies (bold red edges). We provide three example applicat
three ways in which the network can be used to make actionable predictions. The
regulation by TFs and miRNAs, which can be used to predict synergistically actin
repression; Figure 3); (2) predict combined interventions targeting an miRNA and
processes (Figure 4); and (3) provide mechanistic insights into disease processe
176 Cell Systems 3, 172–186, August 24, 2016that had altered proliferation phenotype in the CRISPR-Cas9
screen (p value = 2.9 3 102; Table S7). Notably, 13 of these
TFs altered proliferation only in the glioma stem cell isolates
(p value = 2.5 3 102; Table S7). The observation that 86% of
the CRISPR-Cas9 TF knockouts had phenotypes in only one gli-
oma stem cell isolate underscores the known variability of such
studies, because of the extensive genetic heterogeneity across
GBM tumors (Brennan et al., 2013). Specifically, knockout of a
particular TF will only show a phenotype in an appropriate ge-
netic context, i.e., a patient-derived cell line in which the specific
TF-associated TRN is perturbed. We expect that future studies
with patient-derived glioma stem cell isolates with a different
spectrum of mutations will provide appropriate context in which
knockouts of additional TFs in the gbmSYGNAL network will
alter proliferation. Thus, the CRISPR-Cas9 screen provided
an unbiased phenotypic demonstration that the gbmSYGNAL
network had deciphered disease-relevant transcriptional regula-
tory interactions directly from patient data.
In addition, three independent sources of evidence also sup-
ported biologically meaningful roles in GBM for a significant frac-
tion of TFs in the gbmSYGNAL network: (1) 8 of the 74 TFs were
also previously implicated in GBM by a regulatory network of 53
TFs that was inferred using a different dataset and a different set
of algorithms (p value = 4.4 3 103; Figure 2C) (Carro et al.,
2010); (2) according to the DisGeNET database (Pin˜ero et al.,
2015) of disease-to-gene associations, 16 of the 74 TFs have
important functions in GBM (p value = 5.2 3 104; Figure 2C;
Table S6); and (3) 33 of the 74 TFs (p value = 2.3 3 102) were
differentially expressed in at least one GBM subtype relative to
post-mortem controls (fold change R 2 and Benjamini-Hoch-
berg [BH]-corrected p value % 0.05; Table S8). In summary,
the gbmSYGNAL network implicated 74 TFs in the regulation
of 3,170 GBM-relevant genes. Of the 74 TFs, 58 had not been
previously associated with GBM.
miRNA Regulation in the gbmSYGNAL Network
We incorporated miRNA regulation into the gbmSYGNAL
network by integrating the Framework for Inference of Regula-
tion by miRNAs (FIRM; Plaisier et al., 2012) into cMonkey2 using
the set-enrichment scoring module. In the context of transcrip-
tional regulation, miRNAs are known predominantly for their abil-
ity to repress transcript levels (Baek et al., 2008); therefore, weAL TRN
or data (from The Cancer Genome Atlas [TCGA]) are analyzed sequentially in
work Analysis (SYGNAL) pipeline.
y using the SYGNAL pipeline to analyze tumor biopsy data from 422 patients
tes specific somatic mutations in causally modulating the expression of a TF(s)
ciatedwith a hallmark of cancer. A summary of the counts for each feature in the
predicted regulator (TF or miRNA). The network is arranged according to the
ork features. The features are split into groups based on their underlying details
R-Cas9 confirmed), and validation (GBM-associated TFs and miRNAs). We
ges): somatic mutations in NF1 and PIK3CA are predicted to modulate the
nes that are associated with four hallmarks of cancer involved in two cancer
As that are implicated in the regulation of biclusters harboring targets of es-
ions of the network predictions, which are followed up in detail. Insets illustrate
network topology lends itself to doing the following: (1) discover combinatorial
g combinatorial perturbations (triangle arrowhead, activation; flat arrowhead,
a drug target that have a high likelihood of acting synergistically on disease
s, such as tumor lymphocyte infiltration (Figures 5 and 6).
AB C
D
(legend on next page)
Cell Systems 3, 172–186, August 24, 2016 177
limited miRNA regulatory predictions to models where the
miRNA had a repressive effect. Altogether, 37 miRNAs were
implicated in the regulation of genes within disease-relevant
biclusters, either because their binding sites were enriched
in the 30 UTRs of co-expressed genes within disease-relevant
blusters (11 miRNAs) or because somatic mutations in the
miRNAs were causally associated with disease-relevant expres-
sion changes (29 miRNAs) (Table S9). Four miRNAs (miR-19b,
miR-23a, miR-128a, and miR-128b) were implicated by both
inference procedures (p value = 2.8 3 107).
Several independent lines of evidence supported the bio-
logical and disease significance of the miRNAs in the
gbmSYGNAL network: (1) 28 miRNAs were implicated in
GBM in manually curated databases of miRNAs dysregulated
and causally associated with human diseases (p value %
4.3 3 103; Figure 2C; Table S10; miR2Disease [Jiang et al.,
2009]; Human miRNA Disease Database [HMDD] [Lu et al.,
2008]); (2) perturbations of seven miRNAs have been shown
to alter cancer phenotypes in GBM (miR-17, mir-15b, miR-21,
miR-34a, miR-128, miR-146, and miR-222); and (3) 25 miRNAs
were also differentially expressed in at least one GBM subtype
relative to post-mortem controls (p value = 1.1 3 102; differen-
tial expression fold change R 2 and BH-corrected p value %
0.05; Table S11). That 28 of the 37 miRNAs have been impli-
cated as dysregulated or causally associated with GBM dem-
onstrates the ability of the SYGNAL pipeline to recapitulate
known regulatory interactions, and the remaining nine miRNAs
demonstrate the potential to discover new biology (miR-33b,
miR-152, miR-181a-3p, miR-223, miR-324, miR-340, miR-
495, miR-513, and miR-551b).
We next screened miR-223 (identified by our analysis) and
miR-1292 (whose expression was not profiled in the TCGA
studies and, therefore, was not included in the gbmSYGNAL
network) for effects on proliferation or apoptosis in a primary
astrocyte cell line (HA) and two GBM-derived cell lines (T98G
and U251). We tested both miRNA’s potential role in regulating
proliferation and apoptosis by introducing miRNA mimics to
simulate overexpression and miRNA inhibitors for knockdown
(Table S12). Overexpression of miR-223 led to significantly low-
ered proliferation and increased apoptosis in normal human as-
trocytes (fold change R 2 and B-H p value % 0.05). However,
miR-223 overexpression marginally increased apoptosis and
had little effect on proliferation in the two GBM cell lines. Thus,
miR-223 does not appear to be an important factor for prolifera-
tion or apoptosis in the GBM cell lines we tested, although it mayFigure 3. Network of Combinatorial TF andmiRNARegulatory Interacti
Emergent Transcriptional Signature Underlying the Synergistic Pheno
Proliferation
(A) Edges link TFs and miRNAs found together in at least one combinatorial regu
(B) Effect of combinatorial TF knockdown with siRNA on proliferation. Single-TF
additive expected combined effect (light green bar), which is compared to the ex
than the expected effect, the effect is synergistic; if it is less than the expected
considered additive.
(C) Significant overlap of 48 genes with higher expression following double knoc
lower expression following single knockdown of either TF (p value < 2.2 3 1016
(D) Fold change for 48 genes is significantly lower following ETV6 or NFKB1 single
knockdown of ETV6 and NFKB1. KD, knockdown; Exp. Comb., expected com
combination; *antagonistic effect with p value% 0.05; **antagonistic effect with p
with p value% 0.01.
178 Cell Systems 3, 172–186, August 24, 2016be important in other GBM cell lines or for other cancer pheno-
types (e.g., angiogenesis or invasion).
Knockdown of miR-1292 significantly reduced proliferation in
normal human astrocytes and the U251 glioma cell line (fold
changeR 2 and B-H p value% 0.05). miR-1292 was expressed
at appreciable levels across all three cells lines (miRNA seqenc-
ing [miRNA-seq] countsR 48 per sample in primary astroctyes
and both GBM cell lines), but expression data for this miRNA
across patient tumors were not available. Thus, predicted influ-
ence of miR-1292 was based entirely on the discovery of its
binding site in the 30 UTRs of genes within disease-relevant
biclusters. Taken together, the gbmSYGNAL network recapitu-
lated much of what was known about miRNA regulation in
GBM and identified ten miRNAs not previously associated with
GBM, of which the effects of miR-1292 were experimentally
validated.
Combinatorial Regulatory Interactions
Nearly 40% of all biclusters in the gbmSYGNAL network (93 of
237 TF- and miRNA-regulated biclusters) were predicted to be
under combinatorial control of two ormore regulators (Figure 2C;
Table S13). Using GBM patient tumor expression data and bidi-
rectional stepwise linear regression, we constructed an additive
combinatorial regulatorymodel that best explains the expression
for each of the 93 bicluster eigengenes (the first principal compo-
nent of the co-regulated genes). There was significant evidence
that 87 of the 93 biclusters were putatively governed by an addi-
tive combinatorial regulatory scheme including two or more reg-
ulators (BH-corrected ANOVA p value % 0.05; Table S13). Of
the 87 additive combinatorial models of bicluster regulation,
58 included two regulators, 17 included three regulators, ten
included four regulators, and two included five regulators. In
the combinatorial models there were 54 TFs and 31 miRNAs
that integrated into 45 TF-TF, 17 miRNA-miRNA, and 25
TF-miRNA combinatorial regulatory interactions (Figure 3A).
We provide the same analyses above with correction for biclus-
ter redundancy in Table S14, and the similarity demonstrates
that bicluster redundancy has not biased these analyses. Even
though biclusters might be redundant, the subtle distinctions
may reflect real differencesbetweenpatients andprocesses, and
future work can address this redundancy through ensemble-
based methods that assign confidence metrics to gene co-
occurrence across biclusters (Brooks et al., 2014).
The 54 TFs in the combinatorial models included 23 of the
26 TFs in the gbmSYGNAL network with significantly alteredons, Effect of Combined Knockdown of TF Pairs on Proliferation, and
typic Effect of ETV6 and NFKB1 Single and Double Knockdowns on
latory model, and the key describes additional information overlays.
knockdowns for each pair (yellow and blue bars) were used to compute Bliss
perimentally observed effect (dark green bar). If the observed effect is greater
effect, then it is antagonistic; and if the two are equivalent, then the effect is
kdown of ETV6 and NFKB1, with the overlapping 247 genes with significantly
), is shown.
-TF knockdown and becomes significantly higher expression following double
bination effect size; Obs. Comb., observed combination effect size; Comb.,
value% 0.01; ***antagonistic effect with p value% 0.001; ##synergistic effect
proliferation in glioma stem cell isolate CRISPR-Cas9 knockouts
(p value = 4.63 103; Figure 3A) and all 13 TFs with glioma-spe-
cific proliferation effects (p value < 2.2 3 1016). This suggests
that a majority of the TFs involved in combinatorial regulatory in-
teractions are functional and disease relevant. Additionally, 44%
of TF-TF, miRNA-miRNA, and TF-miRNA pairs within combina-
torial models had significant binding site co-occurrence within
the corresponding regulatory regions (promoter or 30 UTR) of
bicluster genes (BH-corrected p value% 0.05), suggesting that
the predicted combinatorial regulators are directly interacting
with regulatory regions of the same genes and therebymediating
their co-expression. The ability of the SYGNAL pipeline to un-
cover combinatorial regulatory interactions not only provides
deeper understanding of GBM etiology but also enables strate-
gies for combinatorial interventions.
Effects of Double Knockdown of Combinatorial
Regulators on Proliferation and Apoptosis
It has been demonstrated that combinations ofmaster regulators
can be used to predict synergistic compound pairs (Bansal et al.,
2014). Therefore, we explored whether combinatorial regulation
in the gbmSYGNAL network can facilitate discovery of combina-
torial interventions that lead to additive or synergistic outcomes.
From the list of 87 predicted combinatorial regulatory models,
we selected four pairwise TF combinations (CEBPD-CEBPE,
ELF1-PPARG, ETV6-NFKB1, and IRF1-IKZF1) that maximized
coverage of the following four different criteria (Table S15): (1)
their location in the combinatorial network, (2) the increase in vari-
ance explained by the combinatorial model, (3) whether there are
known interactions among the TFs, and (4) whether there is a sig-
nificant co-occurrence of binding sites among the TFs.
We then assayed the effect of double knockdowns of the four
pairwise combinations in all three cell lines on proliferation and
apoptosis (Tables S16 and S17, respectively). We used the Bliss
independence model (Bliss, 1939) to assess the extent to which
combinatorial effects deviated from an additive model as
follows: (1) additive, combined effect is indistinguishable from
the expected additive effect; (2) antagonistic, combined effect
is less than the expected additive effect; or (3) synergistic,
combined effect is greater than the expected additive ef-
fect. Double knockdown of ETV6 and NFKB1 synergistically
reduced proliferation in the U251 GBM cell line (observed fold
change = 2.22 ± 0.02; expected additive fold change = 1.82;
BH-corrected t test p value = 8.2 3 103; Figure 3B; Table
S16). Double knockdown of CEBPD and CEPBE resulted in an
additive decrease in apoptosis in the U251 GBM cell line
(observed fold change = 1.25 ± 0.12; expected additive fold
change = 1.23; BH-corrected t test p value = 0.67; Table
S17). Finally, double knockdowns of IKZF1-IRF1 and ELF1-
PPARG had antagonistic effects on proliferation and apoptosis,
respectively (Figure 3B; TablesS16andS17).Our results suggest
that the topology of combinatorial regulatory interactions in the
gbmSYGNAL network could potentially accelerate the discovery
of synergistically acting drug combinations.
An Emergent Transcriptional Signature Underlies the
Synergistic Effect of a Pairwise Combination
To elucidate the mechanism(s) underlying the synergistic inter-
action between ETV6 and NFKB1, we analyzed the genome-wide transcriptional consequences of single and double knock-
down of the two TFs in U251 cells. As expected, transcript levels
of both TFs were reduced when knocked down, individually or in
combination (fold change% 1.8 and p value% 0.05). Consis-
tent with their predicted roles as activators, knockdown of each
TF led to significant downregulation for a large number of genes
(ETV6: 287 genes; NFKB1: 1,306 genes; fold change% 2 and
BH-corrected p value% 0.1; Table S18) and significantly fewer
genes were upregulated (ETV6: five genes; NFKB1: seven
genes; fold changeR 2 and BH-corrected p value% 0.1; Table
S18). The downregulated genes were significantly enriched with
predicted targets of the perturbed TF (ETV6: 21 genes and
p value = 0.042; NFKB1: 97 genes and p value = 5.5 3 103).
In addition, a common set of 247 genes was downregulated in
both knockdowns, suggesting a significant overlap in the regula-
tory networks of the two TFs (p value < 2.2 3 1016; Figure 3C).
However, there was not a significant amount of ETV6 and NFKB1
motif co-occurrence in the 247 genes (p value = 0.63), suggest-
ing that their combinatorial influence may be more complicated
than binding to the same promoters.
Relative to the single knockdowns, the double knockdown of
ETV6 and NFKB1 resulted in the upregulation of a significantly
larger number of genes (438 genes; fold change R 2 and
BH-corrected p value % 0.1; Figure 3C) and downregulation
of only 22 genes (fold change % 2 and BH-corrected p value
% 0.1; Figure 3C; Table S18). A significant fraction of the upre-
gulated genes in the double knockdown were downregulated in
the single TF knockdowns (ETV6: 57 genes and p value < 2.2 3
1016; NFKB1: 210 genes and p value < 2.23 1016; Figure 3C).
Notably, 48 upregulated genes in the double knockdown were
among the 247 genes that were downregulated by single
knockdown of both TFs (p value < 2.2 3 1016; Figures 3C
and 3D). This reversal in direction of differential expression for
210 genes and the upregulation of an additional 228 genes
were unexpected given the consequences of single knock-
downs for the TFs. The precise mechanism for this synergistic
anti-proliferative interaction was not readily discernible from the
transcriptome changes, and it is unlikely that we could have
predicted the impact of the double knockdown from the single
knockdowns. While effects like this are to be expected in
a massively combinatorial non-linear network, we have shown
that knowledge of the topology of regulatory interactions
can facilitate the selection of synergistically acting TFs and
miRNAs.
An Approach to Discover Synergistic Combinations of
Inhibitors and miRNA Mimics from the gbmSYGNAL
Network
It has been shown that the simultaneous knockdown of an onco-
gene mRNA and inhibition of its protein activity using a drug
can lead to a synergistic effect (Choi et al., 2012). Therefore,
we systematically screened for synergistic phenotypic effects
of combining miRNA mimics and established inhibitor therapies
that were predicted to target the same oncogene in the
gbmSYGNAL network (Figure 2C; Figure 4A). Inhibitors targeting
49 oncogenes have been considered in treating GBM (Alexander
et al., 2013; Ohka et al., 2012; Patil et al., 2013; Sathornsumetee
et al., 2007; Wen et al., 2006). The gbmSYGNAL network
included 18 of these 49 oncogenes, five of which were predictedCell Systems 3, 172–186, August 24, 2016 179
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Figure 4. Discovering Combinations of Oncogene Inhibitors and miRNA Mimics that Have Synergistic Anti-proliferation and/or Pro-
apoptotic Effects
(A) Pairs of miRNAs and established inhibitors that target the same oncogene in the gbmSYGNAL network were prioritized for subsequent experiments to
discover pairs that have synergistic anti-proliferative and/or pro-apoptotic effects.
(B andC) Significant changes in either relative cellular proliferation (B) or relative caspase 3/7 activity (apoptosis, C) are denoted by the white area of the plots (fold
changeR 1.25 or% 0.8 and BH-corrected p value% 0.05).
(D) Dose-response curve in U251 glioma cell line for miR-486-3p mimic on relative cellular proliferation shows an IC50 of 4.6 nM (red dashed line), and mimic
concentrations chosen for dose-response matrix were 0.5, 2.75, 4.6, 11, and 44 nM (purple dashed lines).
(E) Dose-response curve in U251 glioma cell line for HDAC inhibitor romidepsin on relative proliferation has an IC50 of 1.1 nM (red dashed line), and drug
concentrations chosen for dose-response matrix were 0.167, 0.634, 1.1, 7.3, and 13.5 nM (purple dashed lines).
(F) Dose-response matrix for the effect of miR-486-3p and romidepsin combinations on relative cellular proliferation. Combinations with synergistic anti-pro-
liferative effects on relative cellular proliferation are outlined in cyan (synergy scoreR 2.3). HA, primary human astrocytes; T98G and U251, glioma cell lines.
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to be regulated by at least one miRNA (six miRNAs, seven inhib-
itors, and seven possible combinations; Table S19). We assayed
the consequence of single treatments for the six miRNA mimics
(miR-450a, miR-486-3p, miR-506, miR-511, miR-578, and miR-
892b) and seven inhibitors (erlotinib, gefitinib, imatinib, romidep-
sin, sorafenib, vatalanib, and vorinostat) on proliferation and
apoptosis across the HA, T98G, and U251 cell lines (Figures
4B and 4C). For these studies, we specifically screened for sig-
nificant (BH-corrected p value% 0.05) anti-proliferative (prolifer-
ation fold change % 0.8) and pro-apoptotic (apoptosis fold
change R 1.25) effects, as these are the desired therapeutic
responses when treating cancers.
All inhibitors, as expected, and three miRNAs (miR-486-3p,
miR-506, and miR-892b) had significant anti-proliferative effects
in at least one cell line. Six inhibitors (with the exception of gefi-
tinib) had significant pro-apoptotic effects in at least one cell line,
whereas of the miRNA mimics only miR-892b had a significant
pro-apoptotic effect in HA and T98G cells. Together the single-
agent screens identified six inhibitor-miRNA combinations tar-
geting three oncogenes (FLT1, HDAC5, and KDR) that could
be tested for synergistic anti-proliferative effects and two inhib-
itor-miRNA combinations targeting two oncogenes (FLT1 and
KDR) that could be tested for synergistic pro-apoptotic effects
(Table S19).
We selected romidepsin-miR-486-3p for further experimen-
tation because romidepsin had the strongest effects on prolif-
eration and apoptosis in every cell line, which explains why it
is an attractive therapeutic candidate (Sawa et al., 2004; Sun
et al., 2009). In the gbmSYGNAL network, both romidepsin
and miR-486-3p target HDAC5, which is upregulated in GBM
patient tumors and known to increase proliferation of GBM
cells (Liu et al., 2014). Therefore, we hypothesized that the
potentially synergistic effect of romidepsin and miR-486-3p
on HDAC5 would generate a stronger and longer-lasting treat-
ment. We generated dose-response curves for romidepsin and
miR-486-3p in the U251 cell line (romidepsin IC50 = 1.1 nM,
miR-486-3p IC50 = 4.6 nM; Figures 4D and 4E). Then we
designed a 6 3 6 dose-response matrix with a range of con-
centrations centered on the IC50 of each therapeutic agent (Fig-
ure 4F). Four different combinations from this dose-response
matrix generated synergistic effects (synergy score R 2.3; cu-
mulative log volume = 3.19). Significant synergy was observed
for romidepsin concentrations between 0.167 and 0.634 nM
and miR-486-3p concentrations between 0.5 and 4.6 nM (Fig-
ure 4F). Maximal synergy was observed with a combination
of 0.634 nM romidepsin and 4.6 nM miR-486-3p mimic, which
generated an effect size (fold change = 3.1) that was equiva-
lent to 1.75-fold higher concentration of single treatment with
1.1 nM romidepsin. The effect size of this combination also
was very similar to the effects of 1.85 nM romidepsin that pre-
viously was observed to be anti-proliferative and pro-apoptotic
in GBM cell lines (Sawa et al., 2004). This demonstrates that the
gbmSYGNAL network can facilitate discovery of combinations
of inhibitors and miRNAs that act synergistically on cancer phe-
notypes of GBM cell lines. Applied in a high-throughout frame-
work, this approach could, in turn, aid in the prioritization of
future studies on delivery and dosing that together will help
to assess the therapeutic potential of selected combinations,
such as ETV6-NFKB.NF1 and PIK3CA Modulate IRF1, Which Regulates
Antigen Processing and Presentation and Is Associated
with Tumor Lymphocyte Infiltration
Finally, we demonstrate how the gbmSYGNAL network knits
together layers of biological and clinical data into a cohesive
platform for making deeper and more meaningful insights.
For example, the gbmSYGNAL network links somatic driver mu-
tations in either NF1 or PIK3CA to the upregulation of the TF IRF1
(p value = 4.1 3 104; Figures 2C, 2F, and 5A) that activates the
expression of 27 genes within the bicluster PITA_282 (p value =
1.53 102; Figure 5B), which is associated with increased tumor
lymphocyte infiltration and a worse prognosis. This was particu-
larly interesting because both NF1 and PIK3CA are known GBM
driver mutations (Gonzalez-Perez et al., 2013). Upregulation of
IRF1 led to increased expression of the bicluster PITA_282
genes (R = 0.67; p value < 2.23 1016; Figure 5C) and subtract-
ing out the activation by IRF1 removed the causal influence of
somatic mutations from NF1 and PIK3CA (p value = 0.79; Fig-
ure 5D). Incorporation of somatic homozygous deletion of NF1
into these analyses reinforces these findings (Figure S3).
Furthermore, the IRF1 DNA recognition motif MA0050.1 was
enriched within the promoters of 25 of the 27 genes (MA0050.1
TOMTOM q-value = 6.4 3 107; Figures 6A and 6B), suggesting
that IRF1 directly regulates these genes through binding to their
promoter sequences. Based on the structure of the combinato-
rial regulatory network, IRF1 is a hub because it was included in
12 combinatorial models with as many distinct regulators (Fig-
ure 6A), suggesting it may have additional functions when paired
with other TFs. Knockout of IRF1 in the CRISPR-Cas9 screen led
to increased proliferation in the 0827 glioma stem cell isolate
(fold change = 1.6 and FDR = 4.8 3 10 -2; Table S7).
Rank ordering of the patient tumors based on the median
expression of PITA_282 bicluster genes enriched for specific
GBM subtypes in the tails of the distribution. We found that the
proneural subtype (including the G-CIMP phenotype) was highly
enriched in the bottom quintile and the mesenchymal subtype
was highly enriched in the upper two quintiles (Figures 6C and
6D). Additionally, the PITA_282 bicluster was significantly asso-
ciated with patient survival, where patients with tumors in the up-
per quintile had shorter survival on average relative to patients
whose tumors were in the bottom quintile (hazard ratio [HR] =
1.8; 95% confidence interval [CI] = 1.2 – 2.6; p value = 1.2 3
103; Figure 6E).
The PITA_282 bicluster was associated with four hallmarks of
cancer: tumor-promoting inflammation, evading immune detec-
tion, self-sufficiency in growth signals, and insensitivity to anti-
growth signals (Figures 2C and 2F). More specifically, twelve of
the 27 PITA_282 genes are involved in MHC class I antigen pro-
cessing and presentation machinery (APM) (gene ontology [GO]
0002474; B-H p value = 3.03 109; Figure 6F). Thus, we find that
increased MHC class I APM is associated with reduced survival
of GBM patients. A similar trend was observed in medulloblas-
toma where increased MHC class I APM was associated with
unfavorable prognostic marker expression (Smith et al., 2009).
We then asked whether higher MHC class I APM expression
in patient tumors had any impact on tumor lymphocyte infiltration
asmeasured by pathological assessment (Rutledge et al., 2013).
Tumors with tumor-infiltrating lymphocytes had significantly
increased IRF1 expression (p value = 8.1 3 104), and 15 ofCell Systems 3, 172–186, August 24, 2016 181
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Figure 5. NF1 and PI3KCA Somatic Mutations Modulate IRF1 Expression, Which Activates Expression of the 27 Genes in Bicluster PITA_282
(A) IRF1 expression is significantly upregulated when NF1 or PI3KCA is somatically mutated (p value = 4.1 3 104).
(B) The expression of bicluster PITA_282 is also significantly upregulated by NF1 or PI3KCA somatic mutation (p value = 1.5 3 102).
(C) The expression of bicluster PITA_282 and the TF IRF1 are significantly correlated (R = 0.67, p value < 2.23 1016). Patients are colored based on their GBM
subtype (Figure 6C). Patients with somatically mutated NF1 or PI3KCA are shown with a red asterisk.
(D) Conditioning bicluster PITA_282 expression on the expression of IRF1 destroys the link between bicluster PITA_282 andmutations in NF1 or PI3KCA (p value =
0.79), strongly suggesting that the flow of information is from NF1 or PIK3CA somatic mutations to the TF IRF1, which regulates the genes in bicluster PITA_282.
NS, not significant; *p% 0.05; ***p% 0.001.the 27 genes in PITA_282 had significantly increased expres-
sion with increased numbers of tumor-infiltrating lymphocytes
(p value % 0.05; Table S20). The SYGNAL pipeline integrated
multiple layers of biological and clinical data into the gbmSYNAL
network, and this allowed us to explain how somatic mutations in
NF1 and PIK3CA upregulate IRF1, which in turn activates the
expression of downstream target genes that are associated
with increased lymphocyte infiltration andworse patient survival.
DISCUSSION
We developed the TF-target gene interaction database and the
SYGNAL pipeline to construct TRNs that model the influence
of somatic mutations on TFs and miRNAs and, consequently,
their downstream target genes. The SYGNAL pipeline is power-
ful because it is rooted in an integrative model that stitches
together multi-omic and clinical patient data and incorporates
mechanistic regulatory interactions, which provide the means
to maneuver the system back into a more healthy state. Using
the rich multi-omic TCGA GBM dataset, we constructed the
gbmSYGNAL network, and thereby we discovered 67 regulators
(58 TFs and nine miRNAs) that, to our knowledge, have not been
linked to GBM-associated co-expression signatures.
It is attractive to use small RNA molecules (small interfering
RNA [siRNA] and miRNA mimics or inhibitors) in cancer therapy,
because they modulate the expression of a specific regulator
and, thereby, predictably impact many downstream oncogenic182 Cell Systems 3, 172–186, August 24, 2016genes and processes (Heneghan et al., 2010). Network under-
standing of a complex disease, such asGBMas has been gener-
ated in this work, provides a platform for the prioritization of TFs,
miRNAs, drugs, and their combinations as an alternative to
unconstrained high-throughput screens. Our results combined
with findings from recent work (Bansal et al., 2014) demonstrate
that it is feasible to predict synergistic compound pairs, and
our discovery of a synergistic anti-proliferative effect (ETV6-
NFKB1) from few tests provides proof of principle for potentially
using this approach to discover tailored combinatorial therapies
matched to the characteristics of a patient’s disease. This strat-
egy should be broadly applicable, as the tools developed
to construct the gbmSYGNAL network can be used to construct
similar TRNs for any human disease directly from cross-
sectional patient cohort data that include a compendium of tran-
scriptome profiles.
The discovery of inhibitor-miRNA combinations using the
gbmSYGNAL network took advantage of a similar principle
that synergy can emerge by combining an miRNA mimic with
an inhibitor to target the same oncogene (Choi et al., 2012).
Using this principle, we discovered a synergistic interaction
between romidepsin and miR-486-3p, which can be attributed
to the fact that they both target HDAC5 in the gbmSYGNAL
network. Such synergistic combinations could address at least
two issues in using romidespin for cancer therapy. First, the short
half-life of romidepsin in patients poses a significant challenge to
keep the dosage at a level that is needed to effectively treat
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Figure 6. Bicluster PITA_282 Is Significantly Associated with Patient Survival and Is Regulated by the TF IRF1
(A)MEMEmotif 1 discovered through the SYGNAL pipeline was significantly similar to theMA0050.1 IRF1DNA recognitionmotif (TOMTOM q-value = 6.43 107).
(B) Instances of the MA0050.1 in the promoter regions of genes from bicluster PITA_282 are found near the TSSs of all but two genes (HLA-F and HLA-G).
(C) Expression for genes in bicluster PITA_282, with median expression as the white line, and two SDs shown as a gray outline. Patients on the left side of the red
line are in the bicluster and those on the right are excluded from the bicluster. Dashed gray lines break patients into rank-ordered expression quintiles.
(D) Enrichment of GBM subtypes in rank-ordered quintiles. A positive log10(p value) indicates over-enrichment, and a negative value indicates under-enrichment.
(E) There is a significantly lower survival (HR = 1.8; 95% CI = 1.2 – 2.6; p value = 1.23 103) for patients in the upper quintile (red Kaplan-Meier curve) of bicluster
expression compared to the bottom quintile (blue Kaplan-Meier curve).
(F) Of the 27 PITA_282 genes, 12 are involved in MHC class I APM (red genes).
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tumors (Iwamoto et al., 2011). Therefore, combinations with
other therapies that increase the efficacy of romidepsin could
lengthen the effective treatment window and potentially lead to
better therapeutic outcomes. Second, the synergism generates
similar efficacy at a lower inhibitor dosage, which could, in turn,
help to increase the specificity of the combination treatment and
lessen the toxic side effects present at higher doses (Leha´r et al.,
2009).
We also demonstrated how the gbmSYGNAL network could
be used to glean new biological insights by providing meaningful
linkages across GBM driver mutations (NF1 and PIK3CA), differ-
ential regulation of regulators (IRF1) and their downstream genes
associated with two hallmarks of cancer (evading immune
detection and tumor promoting inflammation), and a cancer
phenotype (tumor lymphocyte infiltration) and clinical outcome
(shorter patient survival). It was known previously that mutations
in NF1 significantly increased the number of tumor-infiltrating
lymphocytes and that tumor-infiltrating lymphocytes were en-
riched in the mesenchymal subtype (Rutledge et al., 2013).
However, the mechanism by which NF1 mutations affected
lymphocyte infiltration into tumors was not known. Through the
gbmSYGNAL network, we were able to provide a plausible
mechanism for IRF1, a TF that is characterized by being an inte-
gral part of the immune response, to regulate antigen processing
and presentation genes, which could feasibly modify the recruit-
ment of lymphocytes and other immune cells to the tumor.
TCGA has assembled clinical, transcriptomic, and genomic
data for a large cohort of patient GBM tumors, with the hope
that they will catalyze innovative treatments and cures. The chal-
lenge with these data has been that each patient tumor contrib-
utes a single snapshot that alone is insufficient to provide insight
into causal or mechanistic underpinnings of the disease within
that patient. We hypothesized that patients with similarly per-
turbed oncogenic processes would have conserved genomic
and molecular patterns, based on which they could be sub-
grouped to provide the statistical power required to map the
underlying dysfunctional network and identify points of interven-
tion to halt oncogenic processes. This was the impetus for devel-
oping the TF-target gene database and the SYGNAL pipelines.
Through our studies applying these tools to GBM, we have
demonstrated that multi-omic data from each patient can be
stitched together to gain clinically/biologically meaningful in-
sights and that the network structure and integration with
orthogonal information (drug targets) can be used to discover
intervention points that can lead to synergistic interactions.
Our SYGNAL pipeline can become a data integration platform
that explains the etiology of a disease and provides the knobs
that can be turned to maneuver the system back to a more
healthy state.
EXPERIMENTAL PROCEDURES
Detailed methods are described in the Supplemental Experimental Proce-
dures, and parameters for algorithms and programs can be found in Table S21.
Constructing a TF-Target Gene Interaction Network
Regulatory sequences for each gene were acquired from the University of
California, Santa Cruz (UCSC) human genome release hg19. Unique TF DNA
recognition motifs were collected from a public DNA recognition motif repos-
itory (JASPAR; Mathelier et al., 2014), a private DNA recognition motif repos-184 Cell Systems 3, 172–186, August 24, 2016itory (TRANSFAC; Matys et al., 2006), protein-binding microarray DNA recog-
nition motif repository (UniPROBE; Newburger and Bulyk, 2009), and a recent
study where they used high-throughput SELEX sequencing to discover DNA
recognition for most human TFs (Jolma et al., 2013). DGFs aggregated across
all tissue and cell lines were acquired from ENCODE (Neph et al., 2012). A gene
was considered a target of a TF if it had at least one significant motif instance in
its cis-regulatory regions that overlapped with a DGF by at least one base pair.
The genomic locations bound by 71 TFs in 148 ChIP-seq experiments (Wang
et al., 2012) were downloaded from the UCSC genome browser. Overlap
p values of each TF versus each ChIP-seq TF-bound gene set were used to
compute the sensitivity and specificity for predicting the TF that was immuno-
precipitated in ChIP-seq studies. The final database of TF-target gene interac-
tions and the location of their motif instances (Synapse: syn5907990; http://
www.synapse.org/#!Synapse:syn5907990) can be downloaded from http://
tfbsdb.systemsbiology.net.
Acquisition of TCGA and Independent Validation Cohort Data
for GBM
All TCGA data were acquired from the Broad Firehose. Validation cohort data
were either downloaded from GEO: GSE7696 and GSE16011 (Gravendeel
et al., 2009; Murat et al., 2008) or EMBL-EBI ArrayExpress: E-MTAB-3073
(Madhavan et al., 2009).
SYGNAL Pipeline
The SYGNAL pipeline is described briefly in the main text and in detail in
the Supplemental Experimental Procedures. The gbmSYGNAL network (Syn-
apse: syn5907990; http://www.synapse.org/#!Synapse:syn5907990) can be
explored and downloaded from http://glioma.systemsbiology.net.
Discovering Combinatorial Regulation
We tested for significant evidence of combinatorial regulation using bidirec-
tional stepwise linear regression, and we computed the significance of the in-
crease in variance explained using ANOVA F-test. Co-occurrence of TF and
miRNA-binding sites was computed using a hypergeometric overlap p value.
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